US/UK/Canada

Share

Contacts

  • Immunovia AB
    Medicon Village Scheelevägen 8 SE-223 63 Lund
    +46 46 275 60 00
    http://www.immunovia.com
    • Pick a time period -
    Tags ( Active)

    Immunovia discovery study published in top protein research journal

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the largest and most comprehensive pancreatic cancer proteomics study done to date.   The discovery study identified 41 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC), the most common form of

    End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding

    LUND (SWEDEN) – As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025.   In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success   As 2024 began, we had recently completed a significant transformation of the company. We were a much smaller, more agile team focused on the development of our next-generation test. This focus—and the talents of the Immunovia team—drove excellent progress in 2024. Key highlights:   · We developed accurate and reliable lab

    Immunovia CEO and board members announce intention to fully exercise their TO2 warrants

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company’s rights issue that was announced on May 20, 2024. Immunovia CEO Jeff Borcherding, one of the company’s largest shareholders based on prior purchases, intends to exercise all warrants he purchased in the recent rights issue. In addition, all board members who currently hold TO2 warrants, Martin Møller, Hans Johansson and Peter Høngaard Andersen, have communicated their intention to fully

    Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024. As a follow up, Immunovia will host a webcast on Tuesday, December 17 at 3 pm CET.     Jeff Borcherding, CEO, Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs and Lisa Ford, PhD, Laboratory Director will present additional details about the results and the implications of the study. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai and

    Immunovia announces financial calendar for financial year 2025/2026

    LUND, SWEDEN – Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2025/2026. Year-End 2024 Report             February 25, 2025  Q1 Report, 2025                     May 14, 2025  Q2 Report, 2025                     August 21, 2025  Q3 Report, 2025                     November 19, 2025 Year-End 2025 Report             February 24, 2026   The Annual General Meeting will be held on May 14, 2025, 11:00 CET. For more information, please contact:Karin

    Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).   In the study of over 1,000 patient samples, the test achieved the primary endpoint, exceeding the predefined accuracy criteria and marking a critical milestone in Immunovia’s mission to increase patient survival through early detection of pancreatic cancer.   Key findings from

    Immunovia to present at the Redeye Technology & Life Science Day

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present at the Redeye Technology & Life Science Day on December 3, hosted by Redeye.   Redeye Technology & Life Science Day gathers over 40 leading Nordic companies for a live-streamed event to showcase the groundbreaking work of these companies. During the event, Immunovia CEO Jeff Borcherding will be present in Stockholm to share the company’s latest developments.   Event attendees are encouraged to take the opportunity to meet with Jeff and Immunovia’s CFO, Karin Almqvist-

    Immunovia Publishes Interim Report for January-September 2024

    July-September 2024 · Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488). · Net earnings amounted to -51.1 MSEK (-38.6). · Earnings per share before and after dilution were -0.73 SEK (-0.91). · Cash flow from operating activities amounted to -21.2 MSEK (-35.6). · Cash and cash equivalents at end of period amounted to 54.2 MSEK (106.7) · New lab staffed and fully operational after rapid implementation and validation was announced on July 2. · Detailed discovery study results for the company’s next-generation early detection test for

    Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas—Inherited Gastrointestinal Cancers

    PHILADELPHIA (USA) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company’s next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC).   The Scientific Committee of the CGA-IGC evaluated and accepted Immunovia’s abstract, which reports outcomes from the company’s model-development study, for presentation at the meeting. Immunovia’s submission was also recognized for inclusion in the Henry Lynch

    Invitation to Immunovia’s Q3 presentation

    LUND (SWEDEN) – Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com   Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.   Telephone numbers and webcast

    Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium

    SAN DIEGO (USA) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic cancer in individuals with increased risk for the disease.   Immunovia will share results from studies of its next-generation test to detect stage 1 and 2 pancreatic cancer, including the discovery study, model-development study, and analytical validation. As reported

    Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfully completing the clinical validation study.  The study seeks to confirm the sensitivity and specificity reported previously in the company’s model-development study of its new test. The trial will be a case-control study evaluating the accuracy of the next-generation test

    Immunovia completes analytical validation of its next-generation pancreatic cancer test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set of parameters, reinforcing the reliability and robustness of the test.  The biomarkers that make up Immunovia’s next-generation test demonstrated excellent performance in a series of experiments. These experiments evaluated over 23 key performance attributes of the next-

    Change in number of shares and votes in Immunovia AB (publ)

    LUND (SWEDEN) – During September 2024, the registered number of shares and votes in Immunovia AB (publ) (“Immunovia”) has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to underwriters in the rights issue resolved by the board of directors on 12 September 2024, based on the authorization granted by the annual general meeting on 19 June 2024. As of 30 September 2024, the registered number of shares and votes in Immunovia amounts to 169,711,476.

    Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).   Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test’s performance and stability. In the study of 623 patient samples,

    Immunovia carries out a directed issue of units to guarantors in connection with the completed rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.   LUND (SWEDEN) – The board of directors of Immunovia AB (publ) (”Immunovia” or ”the Company”), has today, based on the authorization granted by the annual general meeting on 19 June 2024, resolved on a directed issue of

    Immunovia announces final outcome in rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.                                                                                                  LUND (SWEDEN) – The board of directors of Immunovia AB (publ) (“Immunovia” or the “Company”) today announces the final

    Immunovia publishes preliminary outcome in rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.                                                                                                  LUND (SWEDEN) – Immunovia AB (publ) (“Immunovia” or the “Company”) today announces the preliminary outcome of the rights

    Immunovia publishes prospectus in connection with forthcoming rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.                                                                                                  LUND (SWEDEN) – The board of directors of Immunovia AB (publ) ("Immunovia" or the "Company") has prepared a prospectus (

    Immunovia announces final terms of rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.     LUND (SWEDEN) – On 20 May 2024, the board of directors of Immunovia AB (“Immunovia” or the “Company”) resolved on an issue of units, consisting of shares and warrants, with preferential rights for the Company’s

    Immunovia Publishes Interim Report for January-June 2024

    April-June 2024 · Net sales, consisting of royalties, amounted to 85 KSEK (412) · Net earnings amounted to -25.6 MSEK (-185.1), where one-off costs second quarter 2023 of 141 MSEK impact comparability between the years. · Earnings per share before and after dilution were -0.57 SEK (-4.00). · Cash Flow from operating activities amounted to -28.2 MSEK (-43.3). · Cash and equivalents at the end of the period amounted to 36.8 MSEK (143.9). · The successful development of accurate and precise assays to measure targeted proteins for the next-generation test was announced on

    Immunovia’s next generation test to be included in large study of pancreatic cysts funded by the U.S. National Institutes of Health

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company’s next-generation test to detect pancreatic cancer has been selected for inclusion in a US-government-funded study to evaluate biomarker tests for monitoring cystic tumors of the pancreas.   The study’s lead author is Diane M. Simeone, an internationally recognized expert in pancreatic neoplasms and the Director of Moores Cancer Center at University of California San Diego Health.   The study will assess the use of biomarker tests to detect pancreatic

    Immunovia files US patent application to protect its next-generation test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces the company has filed a US provisional patent application to protect the intellectual property embodied in its next-generation test to detect stage 1 and 2 pancreatic cancer.   The patent application claims methods of diagnosing pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The company is seeking patent protection for the unique combination of five specific biomarkers used in its test, as well as the method for combining these

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media